<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00731692</url>
  </required_header>
  <id_info>
    <org_study_id>CFTY720D2306</org_study_id>
    <secondary_id>2007-002627-32</secondary_id>
    <nct_id>NCT00731692</nct_id>
    <nct_alias>NCT01779934</nct_alias>
  </id_info>
  <brief_title>This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.</brief_title>
  <acronym>INFORMS</acronym>
  <official_title>A Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5mg Fingolimod Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis and An Open-label, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether FTY720 is effective in delaying MS
      disability progression compared to placebo in patients with PPMS. This was an open-label,
      single-arm extension study to a double-blind, randomized multicenter, placebo-controlled,
      parallel-group core study. The core study completed and eligible patients enrolled into the
      extension study at the next scheduled or unscheduled core study visit. All patients,
      regardless of their treatment in the core study, received fingolimod 0.5 mg in the extension
      study. The extension study was terminated early after the results of the core study became
      available showing that the study did not meet its primary endpoint which was defined as
      confirmed disability progression in this population
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The extension study was terminated early after the results of the core study showed the study
    did not meet primary endpoint; confirmed disability progression
  </why_stopped>
  <start_date type="Actual">July 28, 2008</start_date>
  <completion_date type="Actual">June 22, 2015</completion_date>
  <primary_completion_date type="Actual">June 22, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint</measure>
    <time_frame>up to 36 months after the last patient was randomized</time_frame>
    <description>3-month sustained increase from Baseline in EDSS (at least 1 point increase from Baseline for patients with a Baseline value of 5 or less or at least 0.5 point increase from Baseline for patients with a Baseline value of 5.5 or more) or 3-month sustained increase of at least 20% from BL in the time taken to complete the timed 25-foot walk test (25' TWT); or 3-month sustained increase of at least 20% from BL in the time taken to complete the 9-HPT. The 25' TWT is a quantitative measure of lower extremity function. The EDSS is a scale assessing neurologic impairment, including a series of scores in each of 8 functional systems: Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. The score ranges from 0 (normal) to 10 (death due to MS)). The 9-hole peg test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>up to 36 months after the last patient was randomized</time_frame>
    <description>The Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in MS (Kurtzke 1983) and includes a series of scores in each of 8 functional systems and the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Fatigue is not included in the Cerebral score of the EDSS. The score ranges from 0 (normal) to 10 (death due to MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Brain Volume at Month 36</measure>
    <time_frame>Baseline to month 36</time_frame>
    <description>The percent change from Baseline in brain volume was analyzed using a random coefficients model. The model included: 1) fixed effects: treatment and region and 2) continuous covariates: time, number of Gd enhancing lesions at Baseline, Baseline T2 volume, and normalized brain volume at Baseline. Time as a continuous covariate allowed for the estimation of different slopes and intercepts among treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.</measure>
    <time_frame>up to 36 months after the last patient was randomized</time_frame>
    <description>The 9-HPT is a quantitative measure of upper extremity (arm and hand) function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.</measure>
    <time_frame>up to 36 months after the last patient was randomized</time_frame>
    <description>The 25' TWT is a quantitative measure of lower extremity function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36</measure>
    <time_frame>Baseline to 36 months</time_frame>
    <description>Inflammatory disease, as measured by number of new or newly-enlarging T2 lesions, was assessed by Magnetic resonance Imaging (MRI) scanning of the brain and full spinal cord. N= Total number of patients included in the analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Gd-enhancing Lesions at Month 36</measure>
    <time_frame>Baseline to 36 months</time_frame>
    <description>Inflammatory disease, as measured by number of T1 Gd-enhancing lesions, was assessed by MRI scanning of the brain and full spinal cord. N= Total number of patients included in the analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Total T2 Lesion Volume From Baseline to Month 36</measure>
    <time_frame>Baseline to month 36</time_frame>
    <description>Inflammatory disease as measured by percent change in total T2 lesion volume (mm3) was assessed by MRI. N= Total number of patients included in the analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)</measure>
    <time_frame>Baseline, 36 months</time_frame>
    <description>The quality of life scale contains 22 items. Each item will be given a score of 1 or 0. A score of 1 (or 0) indicates the presence (or absence) of the symptom or adverse quality of life. All 22 item scores will be summed to obtain a total score ranging from 0 (good) to 22 (poor), which is the PRIMUS QoL scale score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in PRIMUS-Activities</measure>
    <time_frame>Baseline, 36 months</time_frame>
    <description>The activities subscale of PRIMUS contains 15 items and each item is given a score of 0 (able to do on own without difficulties), 1 (able to do on own with difficulties), or 2 (unable to do on own). All 15 items were summed to obtain a total score ranging from 0 (good) to 30 (poor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score</measure>
    <time_frame>Baseline, 36 months</time_frame>
    <description>Unidimensional Fatigue Impact Scale (U-FIS), contains 22 patient-reported items that assess the impact of fatigue on cognitive, physical, and psychosocial functioning. Responses formed a single unidimensional scale measuring fatigue impact. The U-FIS was calculated and analyzed according to the U-FIS scoring manual. The U-FIS scale contains 22 items with 5 possible outcomes for each item. Two response categories (about half the time and a lot of the time) were combined into 1 category to obtain 4 possible outcomes: 0 (never), 1 (a little of the time), 2 (about half the time/a lot of the time), and 3 (all the time). The 22 condensed item scores were summed to obtain a total score ranging from 0 (no fatigue) to 66 (severe fatigue impact).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in European Quality of Life - 5 Dimensions (EQ-5D Score)</measure>
    <time_frame>Baseline, 36 months</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)</measure>
    <time_frame>Baseline, 36 months</time_frame>
    <description>The Multiple Sclerosis Walking Scaleis a patient reported measure of walking quality (Hobart et al 2003), consisting of 12 items asking patients to rate the impact of MS upon their walking ability. Responses were captured on a 3-point scale ranging from 1 (Not at all) to 3 (A lot) for items 1 to 3 and on a 5-point scale ranging from 1 (not limited) to 5 (extremely) for items 4 to 12. All 12 item scores were summed to obtain a total score ranging from 12 (good) to 54 (poor) which is the MSWS-12 scale score. The total score was transformed to a 0 to 100 scale score. The MSWS-12 scale score will be transformed to a 0-100 scale score before any summaries or statistical analyses are performed. The transformed score is obtained by subtracting 12 and divided by 42 and multiplying by 100 (i.e., transformed scale score = (raw scale score- 12)/42*100).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Concentrations of Fingolimod and Fingolimod-phosphate</measure>
    <time_frame>Month 3 up to 36 months</time_frame>
    <description>Concentrations of fingolimod and fingolimod-phosphate in whole blood were determined by validated liquid chromatography methods with tandem mass spectrometry. The lower limits of quantification were 0.08 ng/ml for fingolimod and 0.1 ng/ml for fingolimod-phosphate.
Venous blood samples were collected for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MSFC Z-score and Subscale Scores From Baseline to Month 36</measure>
    <time_frame>Baseline to Month 36</time_frame>
    <description>The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">970</enrollment>
  <condition>Primary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>FTY720D 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cohort 1 and 2: Patients randomized to placebo continued on placebo after re-randomization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTY720D 1.25 mg switch to 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment on Nov 2009</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FTY720</intervention_name>
    <description>Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily</description>
    <arm_group_label>FTY720D 0.5 mg</arm_group_label>
    <arm_group_label>FTY720D 1.25 mg switch to 0.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo capsules were administered orally once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        General

          1. sign written informed consent prior to participating in the study

          2. 25 through 65 years of age inclusive

          3. females of childbearing potential must:

               -  have a negative pregnancy test at Baseline (prior to randomization) and

               -  use simultaneously two forms of effective contraception during the treatment and
                  3-months after discontinuation of study medication

        Primary Progressive Multiple sclerosis.

          1. diagnosis of primary progressive multiple sclerosis (according to the 2005 Revised
             McDonald criteria):

          2. time since first reported symptoms between 2 and 10 years

          3. evidence of clinical disability progression in the 2 years prior to Screening

          4. disability status at Screening

               -  EDSS score of 3.5-6.0 inclusive

               -  pyramidal functional system score of 2 or more

               -  25'TWT less than 30 seconds

        Extension study Inclusion criteria

          -  Patients initially randomized to fingolimod 1.25 mg or placebo as part of the first
             study cohort, were to have completed at least 3 years on study drug treatment at the
             time of extension study initiation.

          -  Patients initially randomized to fingolimod 0.5 mg or placebo as part of the second
             study cohort, were to have continued on study drug treatment until such time as the
             last ongoing patient enrolled in the study had reached 3 years in study

        Exclusion Criteria:

        PPMS specific:

          -  History of relapses/attacks

          -  Progressive neurological disorder other than PPMS

          -  Pure cerebellar syndrome or pure visual progressive syndrome or pure

          -  cognitive progressive syndrome

          -  Presence of spinal cord compression at screening MRI

          -  Relevant history of vitamin B12 deficit

          -  Evidence of syphilis or borreliosis at Screening

        Cardiovascular conditions:

          -  Myocardial infarction within the past 6 months or current unstable ischemic heart
             disease

          -  History of angina pectoris due to coronary spasm or history of Raynaud's phenomenon

          -  Severe cardiac failure or cardiac arrest

          -  History of symptomatic bradycardia

          -  Resting pulse &lt;55 bpm pre-dose

          -  History of sick sinus syndrome or sino-atrial heart block

          -  History or presence of second and third degree AV block or an increase QT interval
             (QTc&gt;440 ms)

          -  Arrythmia requiring treatment with class III antiarrythmic drugs

          -  History of positive tilt test from workout of vasovagal syncope

          -  Hypertension, not controlled with medication

        Pulmonary:

          -  Severe respiratory disease or pulmonary fibrosis

          -  TB

          -  Abnormal X-ray, suggestive of active pulmonary disease

          -  Abnormal PFT: &lt;70% of predicted for FEV1 and FVC; &lt;60% for DLCO

          -  Patients receiving chronic (daily) therapies for asthma

        Hepatic:

          -  Known history of alcohol abuse, chronic liver or biliary disease

          -  Total or conjugated Brb &gt;ULN, unless in context of Gilbert's syndrome

          -  AP &gt;1.5xULN; ALT/AST &gt;2xULN; GGT&gt;3xULN

        Other:

          -  History of chronic disease of the immune system other than MS

          -  Malignancy (other than successfully treated SCC or BCC)

          -  Diabetes Mellitus

          -  Macular Edema present at screening

          -  HIV, Hepatitis C or B, other active infection

          -  History of total lymphoid irradiation or bone marrow transplantation

          -  Serum creatinine &gt;1.7 mg/dl

          -  WBC &lt;3500 cells/mm3

          -  Lymphocyte count &lt;800 cells/mm3

          -  History of substance abuse or any other factor that may interfere with subject ability
             to cooperate and comply with the study procedures

          -  Unable to undergo MRI scans

          -  Participation in any therapeutical clinical research study in the 6 months prior to
             randomization

          -  Pregnant or lactating women

          -  Drugs requiring wash-out period:

             3 months:

               -  Systemic corticosteroids or ACTH

               -  INF-beta

                  6 months:

               -  Immunosuppressive medication

               -  Immunoglobulins

               -  Monoclonal antibodies

          -  Drugs that exclude participation in the study:

          -  Cladribine

          -  Cyclophosphamide

          -  Mitoxantrone (except: patients who received a cumulative dose of no more than 60mg/m2
             more than 5 years ago could enter the study)

        Extension study Exclusion criteria

        -Patients were not eligible for enrollment in the extension study if they had any of the
        following key exclusion criteria at the extension study Baseline visit: active chronic
        immune system disease other than MS (or stable disease treated with immune therapy); known
        immunodeficiency syndrome; active infection; uncontrolled diabetes mellitus; macularedema;
        treatment with Class Ia or III antiarrhythmic drugs; any of the specified cardiac,
        pulmonary, or hepatic conditions; or any medically unstable condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pompano Beach</city>
        <state>Florida</state>
        <zip>33060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brookline</city>
        <state>Massachusetts</state>
        <zip>02445</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>11794</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37934</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>2170</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <zip>7000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Box Hill</city>
        <state>Victoria</state>
        <zip>3128</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melsbroek</city>
        <zip>1820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sint-Truiden</city>
        <zip>3800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6R 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burnaby</city>
        <state>British Columbia</state>
        <zip>V5G 2X6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 4K4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J9J 0A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2J2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>656 91</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <state>Czech Republic</state>
        <zip>516 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc</city>
        <state>CZE</state>
        <zip>775 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 29</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aarhus</city>
        <zip>8000 C</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sønderborg</city>
        <zip>6400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux Cedex</city>
        <zip>F-33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille cedex 05</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes</city>
        <zip>35043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hennigsdorf</city>
        <zip>16761</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Teupitz</city>
        <zip>15755</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trier</city>
        <zip>54292</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veszprem</city>
        <zip>H-8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montichiari</city>
        <state>BS</state>
        <zip>25018</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chieti</city>
        <state>CH</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cefalù</city>
        <state>PA</state>
        <zip>90015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orbassano</city>
        <state>TO</state>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gallarate</city>
        <state>VA</state>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <state>CK</state>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435 CM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sittard-Geleen</city>
        <zip>6162 BG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lodz</city>
        <zip>90-153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <state>Andalucia</state>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <state>Catalunya</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Girona</city>
        <state>Catalunya</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lleida</city>
        <state>Catalunya</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bilbao</city>
        <state>Pais Vasco</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goeteborg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zuerich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Atakum / Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Balcova / Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yenisehir / Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salford</city>
        <state>Manchester</state>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>W8 6RF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norwich</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <results_first_submitted>December 16, 2015</results_first_submitted>
  <results_first_submitted_qc>May 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FTY720, primary progressive multiple sclerosis,PPMS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fingolimod Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were randomized equally to receive either fingolimod or placebo. Patients initially randomized to fingolimod 1.25 mg/day or matching placebo groups switched in a blinded manner to fingolimod 0.5 mg/day or continued on placebo after amendment in Nov. 2009. Patients were randomized to receive either fingolimod 0.5 mg/day or placebo..</recruitment_details>
      <pre_assignment_details>Prior to protocol amendment 147 patients received 1.25mg of FTY720; post protocol amendment 5 not all 147 patients switched to 0.5mg FTY720, only 121 switched and their data is presented under the 0.5mg dose.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>FTY720 1.25 mg to 0.5 mg</title>
          <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment</description>
        </group>
        <group group_id="P2">
          <title>FTY720 0.5 mg to 0.5 mg</title>
          <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
        </group>
        <group group_id="P3">
          <title>Placebo to -FTY 0.5 mg</title>
          <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Core Study (36 Months)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="147"/>
                <participants group_id="P2" count="336"/>
                <participants group_id="P3" count="487"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set (SAF)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="336"/>
                <participants group_id="P3" count="487"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="336"/>
                <participants group_id="P3" count="487"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pharmacokinetic Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
                <participants group_id="P2" count="249"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Post Protocol Amendment 5 Switch</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="121">post protocol amendment 121 patients switch to 0.5 mg dose from 125mg dose</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="220"/>
                <participants group_id="P3" count="317"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="116"/>
                <participants group_id="P3" count="170"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="64"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Test Procedure Result</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal Lab values</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="28"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="301"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="196"/>
                <participants group_id="P3" count="301"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Admin Problems: Terminated # patients</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="189"/>
                <participants group_id="P3" count="277"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal test procedure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Abnormal lab values</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>FTY720 1.25 mg to 0.5 mg</title>
          <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment</description>
        </group>
        <group group_id="B2">
          <title>FTY720 0.5 mg to 0.5 mg</title>
          <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="147"/>
            <count group_id="B2" value="336"/>
            <count group_id="B3" value="487"/>
            <count group_id="B4" value="970"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.8" spread="8.47"/>
                    <measurement group_id="B2" value="48.5" spread="8.59"/>
                    <measurement group_id="B3" value="48.5" spread="8.31"/>
                    <measurement group_id="B4" value="48.5" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Particpants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 to 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="90"/>
                    <measurement group_id="B4" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 to 50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="194"/>
                    <measurement group_id="B4" value="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="143"/>
                    <measurement group_id="B3" value="199"/>
                    <measurement group_id="B4" value="396"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="235"/>
                    <measurement group_id="B4" value="469"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="173"/>
                    <measurement group_id="B3" value="252"/>
                    <measurement group_id="B4" value="501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint</title>
        <description>3-month sustained increase from Baseline in EDSS (at least 1 point increase from Baseline for patients with a Baseline value of 5 or less or at least 0.5 point increase from Baseline for patients with a Baseline value of 5.5 or more) or 3-month sustained increase of at least 20% from BL in the time taken to complete the timed 25-foot walk test (25’ TWT); or 3-month sustained increase of at least 20% from BL in the time taken to complete the 9-HPT. The 25’ TWT is a quantitative measure of lower extremity function. The EDSS is a scale assessing neurologic impairment, including a series of scores in each of 8 functional systems: Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. The score ranges from 0 (normal) to 10 (death due to MS)). The 9-hole peg test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function.</description>
        <time_frame>up to 36 months after the last patient was randomized</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Risk of 3-month Confirmed Disability Progression Based on Composite Endpoint</title>
          <description>3-month sustained increase from Baseline in EDSS (at least 1 point increase from Baseline for patients with a Baseline value of 5 or less or at least 0.5 point increase from Baseline for patients with a Baseline value of 5.5 or more) or 3-month sustained increase of at least 20% from BL in the time taken to complete the timed 25-foot walk test (25’ TWT); or 3-month sustained increase of at least 20% from BL in the time taken to complete the 9-HPT. The 25’ TWT is a quantitative measure of lower extremity function. The EDSS is a scale assessing neurologic impairment, including a series of scores in each of 8 functional systems: Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. The score ranges from 0 (normal) to 10 (death due to MS)). The 9-hole peg test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function.</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" lower_limit="71.87" upper_limit="82.51"/>
                    <measurement group_id="O2" value="80.3" lower_limit="73.31" upper_limit="87.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.544</p_value>
            <method>Regression, Cox</method>
            <param_type>Cox Proportional Hazard</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)</title>
        <description>The Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in MS (Kurtzke 1983) and includes a series of scores in each of 8 functional systems and the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Fatigue is not included in the Cerebral score of the EDSS. The score ranges from 0 (normal) to 10 (death due to MS)</description>
        <time_frame>up to 36 months after the last patient was randomized</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan-Meier Estimate of the Risk of 3- Month Confirmed Disability Progression Based on Expanded Disability Status Scale (EDSS)</title>
          <description>The Expanded Disability Status Scale (EDSS) is a scale for assessing neurologic impairment in MS (Kurtzke 1983) and includes a series of scores in each of 8 functional systems and the EDSS steps (ranging from 0 (normal) to 10 (death due to MS)). The functional systems are Visual, Brain Stem, Pyramidal, Cerebellar, Sensory, Bowel and Bladder, Cerebral and Other functions. Fatigue is not included in the Cerebral score of the EDSS. The score ranges from 0 (normal) to 10 (death due to MS)</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="336"/>
                <count group_id="O2" value="487"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" lower_limit="47.16" upper_limit="61.45"/>
                    <measurement group_id="O2" value="58.7" lower_limit="53.30" upper_limit="64.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Brain Volume at Month 36</title>
        <description>The percent change from Baseline in brain volume was analyzed using a random coefficients model. The model included: 1) fixed effects: treatment and region and 2) continuous covariates: time, number of Gd enhancing lesions at Baseline, Baseline T2 volume, and normalized brain volume at Baseline. Time as a continuous covariate allowed for the estimation of different slopes and intercepts among treatment groups.</description>
        <time_frame>Baseline to month 36</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. N= Total number of patients included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Brain Volume at Month 36</title>
          <description>The percent change from Baseline in brain volume was analyzed using a random coefficients model. The model included: 1) fixed effects: treatment and region and 2) continuous covariates: time, number of Gd enhancing lesions at Baseline, Baseline T2 volume, and normalized brain volume at Baseline. Time as a continuous covariate allowed for the estimation of different slopes and intercepts among treatment groups.</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. N= Total number of patients included in the analysis.</population>
          <units>Percent Change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="293"/>
                <count group_id="O2" value="421"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.49" lower_limit="-1.64" upper_limit="-1.35"/>
                    <measurement group_id="O2" value="-1.53" lower_limit="-1.65" upper_limit="-1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.</title>
        <description>The 9-HPT is a quantitative measure of upper extremity (arm and hand) function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis</description>
        <time_frame>up to 36 months after the last patient was randomized</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 9-HPT.</title>
          <description>The 9-HPT is a quantitative measure of upper extremity (arm and hand) function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
          <units>Percentge of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.</title>
        <description>The 25' TWT is a quantitative measure of lower extremity function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis</description>
        <time_frame>up to 36 months after the last patient was randomized</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Kaplan Meier Estimate -Percentage of Participants With 3- Month Confirmed Disability Progression Based on 25' TWT.</title>
          <description>The 25' TWT is a quantitative measure of lower extremity function designed and validated for evaluation of MS patients. N= Total number of patients included in the analysis</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.8"/>
                    <measurement group_id="O2" value="56.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36</title>
        <description>Inflammatory disease, as measured by number of new or newly-enlarging T2 lesions, was assessed by Magnetic resonance Imaging (MRI) scanning of the brain and full spinal cord. N= Total number of patients included in the analysis</description>
        <time_frame>Baseline to 36 months</time_frame>
        <population>Full analysis set (FAS) -The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Number of New/Enlarging T2 Lesions Per Year Measured From Baseline to Month 36</title>
          <description>Inflammatory disease, as measured by number of new or newly-enlarging T2 lesions, was assessed by Magnetic resonance Imaging (MRI) scanning of the brain and full spinal cord. N= Total number of patients included in the analysis</description>
          <population>Full analysis set (FAS) -The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
          <units>T2 Lesions per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="421"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" lower_limit="0.10" upper_limit="0.18"/>
                    <measurement group_id="O2" value="0.50" lower_limit="0.40" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Gd-enhancing Lesions at Month 36</title>
        <description>Inflammatory disease, as measured by number of T1 Gd-enhancing lesions, was assessed by MRI scanning of the brain and full spinal cord. N= Total number of patients included in the analysis</description>
        <time_frame>Baseline to 36 months</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Gd-enhancing Lesions at Month 36</title>
          <description>Inflammatory disease, as measured by number of T1 Gd-enhancing lesions, was assessed by MRI scanning of the brain and full spinal cord. N= Total number of patients included in the analysis</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
          <units>Gd-enhanced lesions per patient per scan</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" lower_limit="0.02" upper_limit="0.09"/>
                    <measurement group_id="O2" value="0.21" lower_limit="0.15" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Total T2 Lesion Volume From Baseline to Month 36</title>
        <description>Inflammatory disease as measured by percent change in total T2 lesion volume (mm3) was assessed by MRI. N= Total number of patients included in the analysis</description>
        <time_frame>Baseline to month 36</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Total T2 Lesion Volume From Baseline to Month 36</title>
          <description>Inflammatory disease as measured by percent change in total T2 lesion volume (mm3) was assessed by MRI. N= Total number of patients included in the analysis</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="224"/>
                <count group_id="O2" value="326"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="30.55"/>
                    <measurement group_id="O2" value="8.9" spread="44.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)</title>
        <description>The quality of life scale contains 22 items. Each item will be given a score of 1 or 0. A score of 1 (or 0) indicates the presence (or absence) of the symptom or adverse quality of life. All 22 item scores will be summed to obtain a total score ranging from 0 (good) to 22 (poor), which is the PRIMUS QoL scale score</description>
        <time_frame>Baseline, 36 months</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 1.25 mg to 0.5 mg</title>
            <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment</description>
          </group>
          <group group_id="O2">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Patient Reported Indices in Multiple Sclerosis (PRIMUS-QoL Score)</title>
          <description>The quality of life scale contains 22 items. Each item will be given a score of 1 or 0. A score of 1 (or 0) indicates the presence (or absence) of the symptom or adverse quality of life. All 22 item scores will be summed to obtain a total score ranging from 0 (good) to 22 (poor), which is the PRIMUS QoL scale score</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="150"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2424" spread="4.18444"/>
                    <measurement group_id="O2" value="0.5921" spread="4.77704"/>
                    <measurement group_id="O3" value="0.9597" spread="4.38578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in PRIMUS-Activities</title>
        <description>The activities subscale of PRIMUS contains 15 items and each item is given a score of 0 (able to do on own without difficulties), 1 (able to do on own with difficulties), or 2 (unable to do on own). All 15 items were summed to obtain a total score ranging from 0 (good) to 30 (poor).</description>
        <time_frame>Baseline, 36 months</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 1.25 mg to 0.5 mg</title>
            <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment</description>
          </group>
          <group group_id="O2">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in PRIMUS-Activities</title>
          <description>The activities subscale of PRIMUS contains 15 items and each item is given a score of 0 (able to do on own without difficulties), 1 (able to do on own with difficulties), or 2 (unable to do on own). All 15 items were summed to obtain a total score ranging from 0 (good) to 30 (poor).</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="153"/>
                <count group_id="O3" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5504" spread="7.05241"/>
                    <measurement group_id="O2" value="2.6324" spread="6.22256"/>
                    <measurement group_id="O3" value="2.8830" spread="6.76499"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score</title>
        <description>Unidimensional Fatigue Impact Scale (U-FIS), contains 22 patient-reported items that assess the impact of fatigue on cognitive, physical, and psychosocial functioning. Responses formed a single unidimensional scale measuring fatigue impact. The U-FIS was calculated and analyzed according to the U-FIS scoring manual. The U-FIS scale contains 22 items with 5 possible outcomes for each item. Two response categories (about half the time and a lot of the time) were combined into 1 category to obtain 4 possible outcomes: 0 (never), 1 (a little of the time), 2 (about half the time/a lot of the time), and 3 (all the time). The 22 condensed item scores were summed to obtain a total score ranging from 0 (no fatigue) to 66 (severe fatigue impact).</description>
        <time_frame>Baseline, 36 months</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 1.25 mg to 0.5 mg</title>
            <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment</description>
          </group>
          <group group_id="O2">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Unidimensional Fatigue Impact (U-FIS) Score</title>
          <description>Unidimensional Fatigue Impact Scale (U-FIS), contains 22 patient-reported items that assess the impact of fatigue on cognitive, physical, and psychosocial functioning. Responses formed a single unidimensional scale measuring fatigue impact. The U-FIS was calculated and analyzed according to the U-FIS scoring manual. The U-FIS scale contains 22 items with 5 possible outcomes for each item. Two response categories (about half the time and a lot of the time) were combined into 1 category to obtain 4 possible outcomes: 0 (never), 1 (a little of the time), 2 (about half the time/a lot of the time), and 3 (all the time). The 22 condensed item scores were summed to obtain a total score ranging from 0 (no fatigue) to 66 (severe fatigue impact).</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="154"/>
                <count group_id="O3" value="241"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3197" spread="12.44042"/>
                    <measurement group_id="O2" value="2.8451" spread="14.04769"/>
                    <measurement group_id="O3" value="3.1394" spread="12.20929"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in European Quality of Life – 5 Dimensions (EQ-5D Score)</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
        <time_frame>Baseline, 36 months</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 1.25 mg to 0.5 mg</title>
            <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment</description>
          </group>
          <group group_id="O2">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in European Quality of Life – 5 Dimensions (EQ-5D Score)</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (confined to bed). Scoring formula developed by EuroQoL Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="99"/>
                <count group_id="O2" value="213"/>
                <count group_id="O3" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0332" spread="0.19420"/>
                    <measurement group_id="O2" value="-0.0475" spread="0.26099"/>
                    <measurement group_id="O3" value="-0.0539" spread="0.22383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)</title>
        <description>The Multiple Sclerosis Walking Scaleis a patient reported measure of walking quality (Hobart et al 2003), consisting of 12 items asking patients to rate the impact of MS upon their walking ability. Responses were captured on a 3-point scale ranging from 1 (Not at all) to 3 (A lot) for items 1 to 3 and on a 5-point scale ranging from 1 (not limited) to 5 (extremely) for items 4 to 12. All 12 item scores were summed to obtain a total score ranging from 12 (good) to 54 (poor) which is the MSWS-12 scale score. The total score was transformed to a 0 to 100 scale score. The MSWS-12 scale score will be transformed to a 0-100 scale score before any summaries or statistical analyses are performed. The transformed score is obtained by subtracting 12 and divided by 42 and multiplying by 100 (i.e., transformed scale score = (raw scale score- 12)/42*100).</description>
        <time_frame>Baseline, 36 months</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 1.25 mg to 0.5 mg</title>
            <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment</description>
          </group>
          <group group_id="O2">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Multiple Sclerosis Walking Scale (MSWS-12 Score)</title>
          <description>The Multiple Sclerosis Walking Scaleis a patient reported measure of walking quality (Hobart et al 2003), consisting of 12 items asking patients to rate the impact of MS upon their walking ability. Responses were captured on a 3-point scale ranging from 1 (Not at all) to 3 (A lot) for items 1 to 3 and on a 5-point scale ranging from 1 (not limited) to 5 (extremely) for items 4 to 12. All 12 item scores were summed to obtain a total score ranging from 12 (good) to 54 (poor) which is the MSWS-12 scale score. The total score was transformed to a 0 to 100 scale score. The MSWS-12 scale score will be transformed to a 0-100 scale score before any summaries or statistical analyses are performed. The transformed score is obtained by subtracting 12 and divided by 42 and multiplying by 100 (i.e., transformed scale score = (raw scale score- 12)/42*100).</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. Only subjects with a value at both baseline and at month 36 are included.</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="182"/>
                <count group_id="O3" value="261"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4444" spread="23.81568"/>
                    <measurement group_id="O2" value="5.5616" spread="24.59030"/>
                    <measurement group_id="O3" value="9.5899" spread="23.98316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Concentrations of Fingolimod and Fingolimod-phosphate</title>
        <description>Concentrations of fingolimod and fingolimod-phosphate in whole blood were determined by validated liquid chromatography methods with tandem mass spectrometry. The lower limits of quantification were 0.08 ng/ml for fingolimod and 0.1 ng/ml for fingolimod-phosphate.
Venous blood samples were collected for the analysis.</description>
        <time_frame>Month 3 up to 36 months</time_frame>
        <population>Full analysis set (FAS) -The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. (N). Only participants (n) who provided one or more evaluable blood concentration were included in the pharmacokinetic analysis population. Analysis include 147 patients (cohort 1)</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 1.25 mg to 0.5 mg</title>
            <description>Cohort 1: fingolimod 1.25 group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg after amendment</description>
          </group>
          <group group_id="O2">
            <title>FTY720 1.25mg to 0.5 mg</title>
            <description>fingolimod 1.25mg/0.5 mg group consists of patients who were initially randomized to fingolimod 1.25 mg and switched to fingolimod 0.5 mg</description>
          </group>
          <group group_id="O3">
            <title>FTY720 0.5 mg to 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Concentrations of Fingolimod and Fingolimod-phosphate</title>
          <description>Concentrations of fingolimod and fingolimod-phosphate in whole blood were determined by validated liquid chromatography methods with tandem mass spectrometry. The lower limits of quantification were 0.08 ng/ml for fingolimod and 0.1 ng/ml for fingolimod-phosphate.
Venous blood samples were collected for the analysis.</description>
          <population>Full analysis set (FAS) -The main efficacy analyses were performed using the FAS, in patients who were initially randomized to either FTY 0.5mg or to Placebo. (N). Only participants (n) who provided one or more evaluable blood concentration were included in the pharmacokinetic analysis population. Analysis include 147 patients (cohort 1)</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
                <count group_id="O2" value="102"/>
                <count group_id="O3" value="249"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3 Fingolimod (n=64, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.04" spread="3.11"/>
                    <measurement group_id="O2" value="NA">No evaluable blood concentration available</measurement>
                    <measurement group_id="O3" value="2.58" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 Fingolimod (n=23, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.24" spread="2.21"/>
                    <measurement group_id="O2" value="2.87" spread="1.70"/>
                    <measurement group_id="O3" value="2.55" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 Fingolimod (n=71,155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="2.44" spread="1.15"/>
                    <measurement group_id="O3" value="2.59" spread="1.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 Fingolimod (n=67, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="2.41" spread="1.30"/>
                    <measurement group_id="O3" value="2.64" spread="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 Fingolimod (n=62, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="2.52" spread="1.28"/>
                    <measurement group_id="O3" value="2.60" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 Fingolimod (n=55, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="2.44" spread="1.08"/>
                    <measurement group_id="O3" value="2.63" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment Fingolimod (n=32, 115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="2.02" spread="1.10"/>
                    <measurement group_id="O3" value="2.57" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3 Fingolimod-Phosphate (n=64, 179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="1.73"/>
                    <measurement group_id="O2" value="NA">No evaluable blood concentration available</measurement>
                    <measurement group_id="O3" value="1.40" spread="0.747"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 Fingolimod-Phosphate (n=23, 161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" spread="1.16"/>
                    <measurement group_id="O2" value="1.54" spread="0.871"/>
                    <measurement group_id="O3" value="1.43" spread="0.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 Fingolimod-Phosphate (n=71,155)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="1.34" spread="0.630"/>
                    <measurement group_id="O3" value="1.41" spread="0.758"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 Fingolimod-Phosphate (n=67, 160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="1.35" spread="0.765"/>
                    <measurement group_id="O3" value="1.44" spread="0.790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 30 Fingolimod-Phosphate (n=62, 158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="1.32" spread="0.676"/>
                    <measurement group_id="O3" value="1.48" spread="0.759"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36 Fingolimod-Phosphate (n=55, 118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="1.32" spread="0.591"/>
                    <measurement group_id="O3" value="1.51" spread="0.765"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of treatment Fingolimod-Phosphate (n=32, 115</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Patients switched to 0.5mg. No evaluable blood concentration available</measurement>
                    <measurement group_id="O2" value="1.19" spread="0.618"/>
                    <measurement group_id="O3" value="1.50" spread="0.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in MSFC Z-score and Subscale Scores From Baseline to Month 36</title>
        <description>The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.</description>
        <time_frame>Baseline to Month 36</time_frame>
        <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>FTY720 0.5 mg</title>
            <description>Cohort 2: The 0.5 mg group consists of patients who were directly randomized to fingolimod 0.5 mg (i.e. AFTER the amendment)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Cohort 1 and 2: Patients who started on placebo continued on placebo after re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Change in MSFC Z-score and Subscale Scores From Baseline to Month 36</title>
          <description>The Multiple Sclerosis Functional Composite (MSFC) is a multidimensional clinical outcome measure that includes quantitative tests of leg function/ambulation (Timed 25-Foot Walk), arm function (9-Hole Peg Test), and cognitive function (Paced Auditory Serial Addition Test). The overall MSFC z-score as an average of the three standardized scores derived using baseline data pooled over each treatment arm as reference population. Higher scores reflect better neurological function and a positive change from Baseline indicates improvement.</description>
          <population>Full analysis set (FAS) - The main efficacy analyses were performed using the FAS</population>
          <units>Z-scores</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="193"/>
                <count group_id="O2" value="279"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.189" spread="0.6980"/>
                    <measurement group_id="O2" value="-0.212" spread="0.8468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Core: FTY720 1.25 mg</title>
          <description>Patients who received FTY720 1.25 mg during core</description>
        </group>
        <group group_id="E2">
          <title>Core: FTY720 0.5 mg</title>
          <description>Patients who received FTY720 0.5 mg during core</description>
        </group>
        <group group_id="E3">
          <title>Core: Placebo</title>
          <description>Patients who received Placebo during core</description>
        </group>
        <group group_id="E4">
          <title>Extension: FTY1.25-0.5</title>
          <description>Patients who received FTY20 1.25 mg in core and received 0.5 mg of FTY during Extension</description>
        </group>
        <group group_id="E5">
          <title>Extension: FTY0.5-0.5</title>
          <description>Patients who received FTY20 0.5 mg in core and received 0.5 mg of FTY during Extension</description>
        </group>
        <group group_id="E6">
          <title>Extension: Placebo-FTY0.5</title>
          <description>Patients who received Placebo in core and received 0.5 mg of FTY during Extension</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="117" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia macrocytic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tachycardia paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amblyopia strabismic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cataract cortical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Chorioretinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cystoid macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Intraocular haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Myopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Optic atrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Anal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cholelithiasis obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Blister infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Enterocolitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Herpes zoster infection neurological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Herpes zoster meningomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Myelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Serratia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Systemic mycosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Traumatic renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Foetal heart rate abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>International normalised ratio decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bone swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dysplastic naevus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Medullary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Metastases to kidney</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Osteoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Ovarian cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Arachnoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Myelitis transverse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Optic neuritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Primary progressive multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Progressive multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Quadriparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Uhthoff's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bladder neck sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nephrogenic diabetes insipidus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urethral obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Jessner's lymphocytic infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Lentigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Activities of daily living impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Poor personal hygiene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Arterial spasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Peripheral venous disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="132" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="278" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="406" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="70" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="138" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="43" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="135" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="25" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="301"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="336"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="487"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="196"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="301"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>trialandresults.registries@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

